GLORIA PARK: Open Payments
NPI 1336770205 · CLAY CENTER, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$708 in 32 payments from 11 companies in 2025. Trend: 2023 $1,150 · 2024 $681 · 2025 $708
Food & beverage: $708
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 8 | $196 |
| Supernus Pharmaceuticals, Inc. | 6 | $153 |
| ABBVIE INC. | 5 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $78 |
| Vanda Pharmaceuticals Inc. | 2 | $49 |
| E.R. Squibb & Sons, L.L.C. | 2 | $34 |
| Lundbeck LLC | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $22 |
| Janssen Pharmaceuticals, Inc | 1 | $19 |
Products named: Qelbree, ARISTADA, VRAYLAR, TRINTELLIX, LYBALVI, REXULTI, FANAPT, COBENFY.
Industry payments across KS — which companies pay providers there.
